Oral Oncology
Volume 46, Issue 3 , Pages 209-213 , March 2010

High expression of excision repair cross-complementation group1 protein predicts poor outcome in patients with nasopharyngeal cancer

  • Hyun Woo Lee

      Affiliations

    • Department of Hematology–Oncology, Ajou University School of Medicine, Suwon 443-721, Republic of Korea
    • ,
  • Yoon Ho Hwang

      Affiliations

    • Department of Hematology–Oncology, Ajou University School of Medicine, Suwon 443-721, Republic of Korea
    • ,
  • Jae Ho Han

      Affiliations

    • Pathology, Ajou University School of Medicine, Suwon 443-721, Republic of Korea
    • ,
  • Jin-Hyuk Choi

      Affiliations

    • Department of Hematology–Oncology, Ajou University School of Medicine, Suwon 443-721, Republic of Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 31 219 4920; fax: +82 31 219 5983.
    • ,
  • Seok Yun Kang

      Affiliations

    • Department of Hematology–Oncology, Ajou University School of Medicine, Suwon 443-721, Republic of Korea
    • ,
  • Seong Hyun Jeong

      Affiliations

    • Department of Hematology–Oncology, Ajou University School of Medicine, Suwon 443-721, Republic of Korea
    • ,
  • Mi Sun Ann

      Affiliations

    • Department of Hematology–Oncology, Ajou University School of Medicine, Suwon 443-721, Republic of Korea
    • ,
  • Young Taek Oh

      Affiliations

    • Radiation Oncology, Ajou University School of Medicine, Suwon 443-721, Republic of Korea
    • ,
  • Jang Hee Kim

      Affiliations

    • Pathology, Ajou University School of Medicine, Suwon 443-721, Republic of Korea
    • ,
  • Chul Ho Kim

      Affiliations

    • Otolaryngology, Ajou University School of Medicine, Suwon 443-721, Republic of Korea
    • ,
  • Seung Soo Sheen

      Affiliations

    • Section of Clinical Epidemiology and Biostatistics in Clinical Trial Center, Ajou University School of Medicine, Suwon 443-721, Republic of Korea

Received 26 November 2009 ,Revised 18 December 2009 ,Accepted 21 December 2009.

References 

  1. Cancer incidence in five continents, vol. VII. IARC Sci. Publ.; 1997(143). p. i–xxxiv, 1–1240.
  2. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol. 2002;13(7):1007–1015
  3. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21(4):631–637
  4. Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004;22(22):4604–4612
  5. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16(4):1310–1317
  6. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol. 2004;22(13):2643–2653
  7. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23(27):6730–6738
  8. Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97(7):536–539
  9. Guigay J. Advances in nasopharyngeal carcinoma. Curr Opin Oncol. 2008;20(3):264–269
  10. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res. 2005;11(17):6100–6102
  11. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–991
  12. Murray D, Vallee-Lucic L, Rosenberg E, Andersson B. Sensitivity of nucleotide excision repair-deficient human cells to ionizing radiation and cyclophosphamide. Anticancer Res. 2002;22(1A):21–26
  13. Murray D, Macann A, Hanson J, Rosenberg E. ERCC1/ERCC4 5’-endonuclease activity as a determinant of hypoxic cell radiosensitivity. Int J Radiat Biol. 1996;69(3):319–327
  14. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988;6(10):1653–1664
  15. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res. 1998;4(6):1469–1474
  16. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001;19(23):4298–4304
  17. Yasumatsu R, Nakashima T, Uryu H, Ayada T, Wakasaki T, Kogo R, et al. Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma. Chemotherapy. 2009;55(1):36–41
  18. Kang SY, Oh YT, Han JH, Choi JH, Lim HY, Kim HI, et al. Concurrent chemoradiotherapy in patients with nasopharyngeal cancer: prognostic significance of low expression of bax. Neoplasma. 2006;53(5):450–456
  19. Greene FL. AJCC cancer staging manual. 6 ed.. New York: Springer; 2002;
  20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216
  21. Kaplan E, Meier P. Non-parametric estimations from incomplete observations. J Am Statistical Assoc. 1958;53:457–481
  22. Cox DR. Regression model and life-tables. J Roy Statist Soc Ser. 1972;34:187–220
  23. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann Oncol. 2007;18(1):29–35
  24. Nakao K, Mochiki M, Nibu K, Sugasawa M, Uozaki H. Analysis of prognostic factors of nasopharyngeal carcinoma: impact of in situ hybridization for Epstein-Barr virus encoded small RNA 1. Otolaryngol Head Neck Surg. 2006;134(4):639–645
  25. Vaughan TL, Shapiro JA, Burt RD, Swanson GM, Berwick M, Lynch CF, et al. Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type. Cancer Epidemiol Biomarkers Prev. 1996;5(8):587–593
  26. Lee HW, Han JH, Kim JH, Lee MH, Jeong SH, Kang SY, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer. 2008;59(1):95–104
  27. Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2005;11(6):2215–2221
  28. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998;16(1):309–316
  29. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13(13):3855–3859
  30. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008;99(1):167–172
  31. Yang ZH, Dai Q, Kong XL, Yang WL, Zhang L. Association of ERCC1 polymorphisms and susceptibility to nasopharyngeal carcinoma. Mol Carcinog. 2009;48(3):196–201
  32. Ma BB, Hui EP, Wong SC, Tung SY, Yuen KK, King A, et al. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma-correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol. 2009;20(11):1854–1859

☆ Grant: Grant from Ajou University Medical Center, Suwon, Korea.

PII: S1368-8375(09)01012-4

doi: 10.1016/j.oraloncology.2009.12.007

Oral Oncology
Volume 46, Issue 3 , Pages 209-213 , March 2010

Article Tools

* Image Usage & Resolution